Autophagy Inhibition Enhances Daunorubicin-Induced Apoptosis in K562 Cells

Weidong Han¹, Jie Sun², Lifeng Feng³, KaiFeng Wang¹, Da Li¹, Qin Pan¹, Yan Chen¹, Wei Jin¹, Xian Wang¹, Hongming Pan¹,², Hongchuan Jin²∗

1Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China, 2Laboratory of Cancer Biology, Biomedical Research Center, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Abstract

Anthracyline daunorubicin (DNR) is one of the major antitumor agents widely used in the treatment of myeloid leukemia. Unfortunately, the clinical efficacy of DNR was limited because of its cytotoxicity at high dosage. As a novel cytoprotective mechanism for tumor cell to survive under unfavorable conditions, autophagy has been proposed to play a role in drug resistance of tumor cells. Whether DNR can activate to impair the sensitivity of cancer cells remains unknown. Here, we first report that DNR can induce a high level of autophagy, which was associated with the activation of extracellular signal-regulated kinase 1/2 (ERK1/2). Moreover, cell death induced by DNR was greatly enhanced after autophagy inhibition by the pharmacological inhibitor chloroquine (CQ) and siRNAs targeting Atg5 and Atg7, the most important components for the formation of autophagosome. In conclusion, we found that DNR can induce cytoprotective autophagy by activation of ERK in myeloid leukemia cells. Autophagy inhibition thus represents a promising approach to improve the efficacy of DNR in the treatment of patients with myeloid leukemia.

Introduction

Myeloid leukemia is a heterogeneous group of diseases characterized by uncontrolled proliferation of neoplastic hematopoietic precursor cells and impaired production of normal hematopoiesis leading to neutropenia, anemia, and thrombocytopenia [1]. Anthracyline daunorubicin (DNR) is one of the major antitumor agents widely used in the treatment of myeloid leukemia. The toxicities of DNR include cardiac toxicity, renal toxicity, severe myelosuppression, et al [2,3,4]. Cytotoxicities induced by DNR are mainly caused by drug-induced damage to DNA and production of free radicals which are initiated by reactive oxygen species (ROS) [5,6]. Since the dosage used is critical to the incidence of DNR-induced toxicities, it would be important to reduce the dosage of DNR by increasing the sensitivity of leukemia cells to DNR.

Macroautophagy (hereafter referred to as autophagy) is a degradative process in eukaryotic cells that results in the breakdown of intracellular material within lysosomes [7,8]. Under cellular stress conditions such as nutrient-deprivation, DNA damage and elevation of intracellular ROS, autophagy could be activated to provide an alternative source of energy to enable cell survival [9,10,11]. Excessive or unquenched autophagy, however, can lead to type II programmed cell death (PCD II), which is morphologically distinct from apoptosis and usually caspase independent [12]. In tumor cells, the role of autophagy may depend on the type of tumors, the stage of tumorigenesis, the nature and extent of the insults. Autophagy was upregulated during the later stages of cancer development so that cancer cells could survive in the central areas of the tumour which are usually poorly vascularized and lack of nutrient and oxygen [13,14,15]. A number of anticancer therapies, including DNA-damaging chemotherapeutic drugs, have been observed to induce the accumulation of autophagosomes in tumor cell lines and inhibition of autophagy by pharmacologic inhibitor or genetic knockdown of phylogenetically conserved autophagy-related genes, such as Atg5 and Atg7, usually enhanced drug-induced cytotoxicities [12]. In our previous research, we found that gefitinib induced autophagy in lung cancer cells and inhibiting autophagy increased the sensitivity of lung cancer cells to gefitinib, suggesting a novel approach to enhance target therapy of lung cancer [16].

In the present study, we demonstrated that DNR induced autophagy in myeloid leukemia cells by ERK1/2 activation. And DNR-induced apoptosis was enhanced after the inhibition of autophagy, suggesting a novel and promising strategy to increase the clinical efficacy of DNR for the treatment of myeloid leukemia.

Materials and Methods

Reagents and antibodies

Daunorubicin (DNR) and chloroquine (CQ) were purchased from J&K chemical Ltd., China. Monodansylecadaverine (MDC), U0126 and Hoechst were purchased from Sigma-Aldrich.
antibodies against microtubule-associated protein 1 light chain 3 (LC3), Atg5, Atg7, Beclin-1, caspase 3, caspase 9, PARP, GAPDH, non-phospho- or phospho-MEK1/2 and ERK1/2 were from Cell Signaling Technology, Inc.. The secondary antibodies were HRP conjugated anti-rabbit and anti-mouse IgG (Cell Signaling Technology, Inc.).

Cell cultures and transfection
K562 were bought from cell bank (Chinese Academy of Sciences). Cells was maintained in RPMI 1640 supplemented with 10% (v/v) FBS. Stock solution of U0126 was prepared in dimethyl-sulphoxide (DMSO, Sigma) and diluted with medium before use. Final concentration of DMSO was <0.1%. The tiLC3 tandemly tagged with GFP and mRFP construct were obtained from Addgene. Transfection was performed via electroporation with a Nucleofection system (Amaxa, Inc.) according to the manufacturer’s instructions. Stable transformants were selected in complete medium containing 500 μg/ml G418 (Sigma).

Cytotoxicity assay
The cytotoxicity of chemicals against K562 cells was determined by MTT assay. Cells were seeded into 96-well plates and treated with chemicals with different concentrations. After 48-h incubation, 20 μl MTT (5 mg/ml) was added into each well for 4-h incubation and 150 μl DMSO was added into each well in order to solubilize the blue-purple crystals of formazan afterwards. The absorbance was then measured using a model ELX800 Micro Plate Reader (Bio-Tek Instruments, Inc.) at 570 nm.

MDC-staining and Hoechst-staining
MDC was stored at -20°C under desiccant. A fresh stock solution of 5 mM MDC was made in 1:1 DMSO immediately prior to use. At 1 hour before fixation, fresh medium that contained either 10 μM MDC in DMSO or an equivalent volume of DMSO was added to the cells. The cells were fixed using a freshly made 4% formaldehyde solution in PBS for 10 min. at room temperature and imaged immediately.

For identification of cells with nuclear changes typical of apoptosis, cells were stained with 5 μg/ml of Hoechst 33342 for 10 min. at 4°C in the dark and analyzed using a UV microscope.

Immunofluorescence and confocal microscopy
Cells were collected, fixed and permeabilized with 1% CHAPS buffer (150 mM NaCl, 10 mM HEPES, 1.0% CHAPS) at room temperature for 10 min, incubated with anti-LC3 for 2 h at room temperature, and washed with PBS, incubated for another 45 min with FITC-conjugated goat anti-rabbit IgG (Beyotime, A0562). Then, cell nuclei were stained by DAPI (Sigma, D9564). Samples were examined under a Zeiss LSM 710 confocal microscope system (Carl Zeiss, Germany). Image was processed with ZEN LE software.

For evaluating tandem fluorescent LC3 puncta, stable transformants after treatment were washed with PBS, fixed with 4% paraformaldehyde, mounted with DAPI and viewed under the confocal microscope.

Electron microscopy
Treated cells were washed and fixed for 30 min in 2.5% glutaraldehyde. The samples were treated with 1.5% osmium tetroxide, dehydrated with acetone and embedded in Durcupan resin. Thin sections were poststained with lead citrate and examined in the TECNAI 10 electron microscope (Philips, Holland) at 60 kV.

Western blot analysis
Western blotting was carried out as previously reported [17]. Briefly, proteins were resolved by SDS-polyacrylamide gel electrophoresis, transferred to a PVDF membrane and then detected by the proper primary and secondary antibodies before visualization with a chemiluminescence kit (Pierce). The visualization was done with Image Quant LAS-4000 (Fujifilm, Tokyo, Japan).

RNA interference
K562 cells were transfected with either nonspecific or Atg5/Atg7 RNA interference (All siRNAs were from Qiagen, RNAi; final concentration, 100 nmol/L) via LipofectAMINE 2000 (invitrogen) according to the manufacturer’s instructions. Cells were then incubated for 48 h prior to Western blot or MTT assay.

For Beclin-1 RNA interference, two siRNA oligonucleotides targeting Beclin-1 were bought from Cell Signaling Tech (#6222 & 6246). A nonspecific oligo that is not complementary to any human genes was used as a negative control. To transfect K562 cells, HiPerFect reagent (QIAGEN) was used following the manufacturer’s protocol.

Statistical analyses
Unless otherwise stated, data were expressed as the mean ± SD and analyzed by Student’s t test.

Results
DNR induced apoptosis in K562 cells
K562 cells were incubated in the presence of varying concentration of DNR for 24 hours and subjected to morphological and biochemical examinations. A dose-dependent nuclear morphology changes were observed (Fig. 1A). Cells had typical morphology of apoptosis such as nuclear chromatin condensation and nuclear fragmentation. Biochemically, caspase 3 and 9 were activated by DNR in a dose-dependent manner (Fig. 1B). Consistently, the level of cleaved product of caspases substrate Poly ADP-ribose Polymerase (PARP) was correlated with the activation of caspases (Fig. 1B). Collectively, these results demonstrated that DNR could induce apoptosis in K562 cells.

DNR activated autophagy in K562 cells
To evaluate the activation of autophagy by DNR, the conversion of LC3-I into LC3-II before and after DNR treatment was first determined by western blotting analysis. DNR can induce the switch of LC3-I to LC3-II in the dose and time dependent manner in K562 cells, indicating that autophagy might be activated by DNR (Fig. 2A). Consistently, Beclin-1, a regulator of autophagic pathway, was significantly up-regulated in DNR-activated by DNR in a dose-dependent manner (Fig. 2B). Consistently, the level of cleaved product of caspases substrate Poly ADP-ribose Polymerase (PARP) was correlated with the activation of caspases (Fig. 1B). Collectively, these results demonstrated that DNR could induce apoptosis in K562 cells.
Furthermore, ultrastructural analysis by electron microscopy further confirmed that large autophagic vacuoles with typical double-layer membrane containing organelle remnants presented in DNR-treated K562 cells rather than untreated cells (Fig. 3). Besides, K562 cells treated with 2.5 μg/ml DNR for 12 hours displayed a typical nuclear morphology of apoptosis such as chromatin condensation and nuclear fragmentation (Fig. 3D).

Blockage of autophagy enhanced DNR-induced K562 cell death

Many studies have demonstrated that autophagy may serve as a protective response preventing tumor cells from therapy-induced cell death [10]. To test this consumption, we compared the growth inhibitory effect of DNR on cancer cells before and after pharmacological and genetic inhibition of autophagy. As shown in Figure 4A, CQ failed to inhibit K562 cell growth by its own. However, it significantly inhibited the autophagy induced by DNR (Figure S1) and augmented growth inhibition induced by DNR as well as DNR-induced caspase activation (Fig. 4B).[19]

Autophagy is tightly regulated by several highly conserved molecules called ATGs [11]. Since ATGs are essential to the activation of autophagy, siRNAs specific to human Atg5 and Atg7 were used to block autophagy after DNR treatment (Fig. 5A and B). Consistent with the pharmacological inhibition of autophagy, growth inhibition induced by DNR was markedly enhanced after autophagy was blocked by the knockdown of Atg5 and Atg7 (Fig. 5A and B), confirming that DNR-activated autophagy is cytoprotective.

As mentioned above, Beclin-1, a regulator of autophagic pathway, was significantly up-regulated in DNR-treated cells (Fig. 2B). This result prompted us to investigate if knockdown of Beclin-1 will impair DNR induced autophagy? As expected, knockdown of beclin-1 could significantly decrease the number of puncta LC3 induced by DNR (Fig. 5C&D). And we also measured the cytotoxicity of DNR against K562 cells transfected with beclin-1 siRNAs. Inhibition of autophagy by knockdown of beclin-1 sensitized K562 cells to DNR (Fig 3). E).

DNR induced autophagy by activating of MEK/ERK signaling pathway

It have been reported that autophagy was associated with MAPK signaling pathway [20,21,22,23]. Therefore, we determined the relevance of this pathway to DNR-induced autophagy. Indeed, phosphorylation of MEK1/2 and ERK1/2 were significantly increased after DNR treatment (Fig. 6A). Pre-treatment of K562 cells with the MEK1/2 inhibitor U0126 resulted in the decrease of LC3-II levels (Fig. 6A), indicating the dependence of autophagy on the activation of MAPK signaling. In consistence with previously finding (Fig 4 and 5), U0126 significantly augmented DNR-induced growth inhibition of K562 cells (Fig. 6B).

Discussion

Anthracycline daunorubicin is one of the major antitumor agents widely used in the treatment of myeloid leukemias. Cytotoxicity mediated by DNR is generally thought to be the result of drug-induced damage to DNA. Interestingly, previous studies demonstrated that DNR triggered both apoptotic and survival pathways. The phospholipase C–dependent DAG/raf-1/MEK cascade and DAG independent PI3K/PKC cascade play a significant role in DNR induced cellular survival pathways [24]. As well known, both raf-1/MEK and PI3K cascade are involved in the autophagy signaling [11,25]. In addition to DNR, many other DNA-damaging drugs have been confirmed to activate autophagy in various tumor cell lines and inhibition of autophagy by pharmacologic inhibitors or genetic knockdown of critical autophagy-related genes such as Atg5 and Atg7 could enhance the anti-cancer effect of chemotherapeutic drugs [10]. However, very little was known about the relevance of autophagy in the response of myeloid leukemia cells to DNR treatment. This study, for the first time, demonstrated that DNR can induce cytoprotective autophagy in K562 cells by the activation of MEK/ERK signaling pathway.

Autophagy is morphologically characterized by the appearance of “double-membrane” vacuoles, autophagosomes, in the cyto-
In addition, LC3, the mammalian homologue of the yeast protein Apg8p, was found to be a specific biochemical marker for autophagy. Newly synthesized LC3 termed LC3-I is evenly distributed throughout the cytoplasm. Upon the induction of autophagy, some LC3-I is converted into LC3-II which is tightly bound to the autophagosomal membranes, forming ring-shaped structures in the cytosol. We confirmed biochemically and morphologically that autophagy was activated by DNR in K562 cell lines (Fig. 2 and 3).

In addition, we found that DNR could induce both apoptosis and autophagy in K562 cells (Fig.3 D and E). Inhibition of autophagy enhanced the activation of caspases as well as the tumor inhibition induced by DNR (Fig. 4 and Fig. 5). Based on the EM results, we postulated that autophagy activated by DNR in K562 cells was probably earlier than apoptosis. When K562 cells treated with DNR for 6 hours, we could find numerous autophagical vacuoles with typical double-layer membrane containing organelle remnants in most of cells while the apoptotic changes of nuclei were less observed. However, chromatin condensation and nuclear fragmentation were easier to find only after K562 cells were treated with DNR for 12 hours. This result was consistent with previous reports that autophagy preceded apoptosis in many cancer cells treated with various cytotoxic drugs [26,27,28].

As one critical signaling pathways involved in tumorigenesis, MAPK signaling pathway are often activated in numerous types of cancer cells. Accumulating evidences indicated that the activation of ERK1/2 was associated with autophagy [22,23,29,30,31]. In our study, we found that DNR indeed activated MEK1/2 and ERK1/2. Inhibition of MEK1/2 by U0126 inhibited the shift from LC3-I to LC3-II, thus enhancing the cytotoxic effect of DNR. Previous studies indicted that the constant activation of MEK/ERK signaling in tumor cells could up-regulate Beclin-1, eventually activating autophagy [23]. Indeed, Belin 1 expression in K562 cells was increased after DNR treatment (Fig. 2B). Knockdown of beclin-1 could significantly decrease the number of puncta LC3 induced by DNR (Fig. 5C&D), and sensitized K562 cells to DNR treatment (Fig. 5E).
In summary, our results demonstrated that DNR could induce growth inhibition as well as cytoprotective autophagy in myeloid leukemia cells. Blocking autophagy by autophagy inhibitors or inhibitors of MAPK signaling is a promising therapeutic strategy to enhance tumor inhibition induced by DNR and probably other chemotherapeutic drugs.

Figure 3. TEM depicted ultrastructures of K562 cells treated with DNR. Cells treated without (A) or with 2.5 μg/ml DNR for 6 hours (B, low power; C, high power) and 12 hours (D, low power; E, high power) were subjected to TEM analysis. Autophagosomes were highlighted by white arrows in C and E while apoptotic changes such as chromatin condensation and nuclear fragmentation were highlighted by black arrows in D. Bar = 1 μm. doi:10.1371/journal.pone.0028491.g003

Figure 4. Autophagy inhibitor CQ enhanced DNR-induced apoptosis in K562 cells. A. Cells were treated with varying concentration of DNR for 48 hours in the presence or absence of 5 μM CQ. Cell viability was then measured by MTT assay. B. Immunoblotting of caspase 3, caspase 9 and PARP using lysates from K562 cells as treated in A. Data were expressed as the mean ± SD, and analyzed by Student’s t test. *, P<0.05 and **, P<0.01. doi:10.1371/journal.pone.0028491.g004
Activation of Cytoprotective Autophagy by DNR

Figure 5. Depletion of autophagy genes enhanced DNR-induced apoptosis in K562 cells. A & B, Cells transiently transfected with negative control siRNA, Atg7 or Atg5 siRNA were treated with varying concentration of DNR for 48 hours. Cells viability was measured by MTT assay and the expression of Atg5 and Atg7 were determined by Immunoblotting. C, Cells were transiently transfected with negative control siRNA or beclin-1 targeting siRNAs, and the expression of beclin-1 was determined by western blot. D, Cells were treated with 1.25 μg/ml DNR for 24 hours, and stained by indirect immunofluorescence as described in Material & Methods. The distribution of endogenous LC3 was monitored at confocal microscope. Green, FITC labelled LC3; blue, DAPI stained nuclei. E, Cells transiently transfected with beclin-1 targeting siRNAs were treated with 1.25 μg/ml DNR for 48 hours, and the viability was measured by MTT assay. Data were expressed as the mean ± SD, and analyzed by Student’s t test. * P<0.05, ** P<0.01.
doi:10.1371/journal.pone.0028491.g005

Figure 6. Activation of autophagy by DNR was MEK/ERK-dependent. A, K562 cells were treated with 1.25 μg/ml DNR for 24 hours in the presence or absence of 5 μM U0126 and the switch of LC3-I to LC3-II as well as the phosphorylation of MEK 1/2 and ERK1/2 were determined by Immunoblotting. B, Cells were treated with varying concentration of DNR for 48 hours in the presence or absence of 5 μM U0126. Cells viability was measured by MTT assay. Data were expressed as the mean ± SD, and analyzed by Student’s t test. * P<0.05.
doi:10.1371/journal.pone.0028491.g006
Activation of Cytoprotective Autophagy by DNR

Supporting Information

Figure S1  CQ inhibited DNR-induced autolysosomes formation. K562 cells with stable expression of tLC3 were treated with 1.25 μg/ml DNR for 24 hours in the presence or absence of 5 μM CQ, mRFP and GFP were monitored at confocal microscope as described in M&M. The red puncta that overlay with the green puncta and appear yellow in merged images are indicators of autophagosomes, whereas the free red puncta that do not overlay with the green puncta and appear red in merged images are indicative of autolysosomes [19].

(TIF)

Author Contributions

Conceived and designed the experiments: WH XW HP HJ. Performed the experiments: WH JS LF KW DL QP YC WJ. Analyzed the data: WH XW HP HJ. Wrote the paper: WH XW HJ.

References

1. McCulloch EA (1983) Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture). Blood 62: 1–13.
2. Moretti E, Oakman C, Di Leo A (2009) Predicting anthracycline benefit: have we made any progress? Curr Opin Oncol 21: 507–515.
3. Maral RJ, Jouanne M (1981) Toxicology of daunorubicin in animals and man. Cancer Treat Rep 65(Suppl 4): 9–18.
4. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, et al. (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117: 2355–2365.
5. Boozer DJ, Hortobagyi GN (1994) Anthracycline antibiotics in cancer therapy. Drugs 47: 223–258.
6. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, et al. (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112: 3754–3762.
7. Kroemer G, Jaattela M (2005) Lysosomes and autophagy in cell death control. Nat Rev Cancer 5: 89–97.
8. Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular mechanisms. J Pathol 221: 3–12.
9. Dikie I, Johannsen T, Kirkin V (2010) Selective autophagy in cancer development and therapy. Cancer Res 70: 3431–3438.
10. Livesey KM, Tang D, Zeh HJ, Lester MT (2009) Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs 10: 1269–1279.
11. Klioussi DJ (2007) Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 8: 931–937.
12. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A (2009) Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 16: 966–975.
13. White E, Karp C, Strohecker AM, Guo Y, Mathew R (2010) Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol 22: 212–217.
14. Dikie I, Johannsen T, Kirkin V (2010) Selective autophagy in cancer development and therapy. Cancer Res 70: 3431–3438.
15. White E, DiPaola RS (2009) The double-edged sword of autophagy modulation in cancer. Curr Cancer Res 15: 5308–5316.
16. Weidong Han HP, YanChen, JieSun, YansanWang, Jing Li, et al. (2011) EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells. PLoS One 6(6): e18691.
17. Han W, Li L, Qiu S, Lu Q, Pan Q, et al. (2007) Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 6: 1641–1649.
18. Vazquez CL, Colombo MI (2009) Assays to assess autophagy induction and fusion of autophagic vacuoles with a degradative compartment, using monodansylcadaverine (MDC) and DQ-BSA. Methods Enzymol 452: 83–95.
19. Kimura S, Noda T, Yoshimori T (2007) Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3: 452–460.
20. Ogier-Denis E, Pattingre S, El Benna J, Codogno P (2000) Erk1/2-dependent phosphorylation of Galphα-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. J Biol Chem 275: 39090–39095.
21. Ellington AA, Berhow MA, Singletary KW (2006) Inhibition of Akt signaling and enhanced ERK1/2 activity are involved in induction of macroautophagy by triterpenoid B-group saponins in colon cancer cells. Carcinogenesis 27: 290–300.
22. Shinojima N, Yokoyama T, Kondo Y, Kondo S (2007) Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy 3: 635–637.
23. Wang J, Whiteman MW, Lian H, Wang G, Singh A, et al. (2009) A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1. J Biol Chem 284: 21412–21424.
24. Laurent G, Jaffrezou JP (2003) Signaling pathways activated by daunorubicin. Blood 98: 913–924.
25. Yang Z, Klionsky DJ (2009). An overview of the molecular mechanism of autophagy. Curr Top Microbiol Immunol 335: 1–32.
26. Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T (2007) Autophagy precedes apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull 30: 859–864.
27. Sy LK, Yan SC, Lok GN, Man RY, Che CM (2008) Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells. Cancer Res 68: 10229–10237.
28. Abdrilin MJ, Wang D, McDonnell MA, Lehnmann U, Kelekac A (2007) Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 14: 500–510.
29. Wong CH, Iskandar KB, Yadav SK, Hirpara JL, Loh T, et al. (2010) Simultaneous induction of non-canonical autophagy and apoptosis in cancer cells by ROS-dependent ERK and JNK activation. PLoS One 5: e9996.
30. Corcelle E, Nefout M, Bekri S, Gauthier N, Hofman P, et al. (2006) Disruption of autophagy at the maturation step by the carcinogen lindane is associated with the sustained mitogen-activated protein kinase/extracellular signal-regulated kinase activity. Cancer Res 66: 6861–6870.
31. Chen SY, Chiu LY, Maa MC, Wang JS, Chien CL, et al. (2011) cVAD-induced autophagic cell death requires c-Src-dependent ERK and JNK activation and reactive oxygen species generation. Autophagy 7: 217–228.